FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214443089> ?p ?o ?g. }

• W3214443089 endingPage "3803" @default.
• W3214443089 startingPage "3803" @default.
• W3214443089 abstract "Abstract Background: Treatment of multiple myeloma (MM) commonly encompasses combination of drugs within the three drug classes including proteasome inhibitors (PIs), immunomodulators and (IMiDs), and monoclonal antibodies, both for newly diagnosed and relapsed disease. With increasing appreciation of disease heterogeneity based on underlying genetic abnormality, and demonstration of efficacy of venetoclax in patients with t(11;14) MM, the outcomes with commonly used MM regimens among the different cytogenetic subgroups are of great interest. Venetoclax, a BCL-2 inhibitor, is being studied in t(11;14) positive MM patients who have received at least two prior lines of treatment (NCT03539744; CANOVA). However, outcomes in previously treated t(11;14) MM patients using standard of care approaches in the real-world setting is limited. Patients and methods: This non-interventional, retrospective observational cohort study included patients with t(11;14) MM from the International Myeloma Working Group (IMWG) retrospective study of t(11;14) MM. From the overall cohort, patients with t(11;14) MM receiving pomalidomide + dexamethasone (PomDex) in ≥3 rd line were selected, similar to those being enrolled in the ongoing CANOVA trial. Patients were also required to have prior exposure to lenalidomide and a PI without a history of transplant within 16 weeks prior to PomDex initiation. Patients enrolled in a clinical trial were excluded. Overall best response, time to next therapy (TTNT) as a surrogate measure for progression-free survival (PFS) and overall survival (OS) were assessed after initiation of PomDex. All analyses were descriptive in nature and were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Results: Fifty-two patients who met the inclusion criteria were analyzed. Median age was 63 years, 60% were male. Patients had a median of 3 prior lines at start of PomDex, at a median of 4.3 years from diagnosis; 52% had a prior transplant. A PR or better was observed in 34% of patients with PomDex. The median TTNT for this cohort was 6.1 months and median OS was 19.2 months. Conclusion: This retrospective study of non-trial patients with t(11;14) MM provides a benchmark for newer therapies in this patient population for comparison with both venetoclax dexamethasone in the ongoing CANOVA study as well as combinations using the pomalidomide backbone. Disclosures Karve: AbbVie: Current Employment, Current equity holder in publicly-traded company. Kumar: Roche-Genentech: Consultancy, Research Funding; Bluebird Bio: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Research Funding; Novartis: Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Carsgen: Research Funding; Antengene: Consultancy, Honoraria; Oncopeptides: Consultancy; Beigene: Consultancy; Tenebio: Research Funding; BMS: Consultancy, Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding. Gonzalez De La Calle: Celgene-BMS, Janssen, Amgen: Honoraria. Mangiacavalli: GSK: Honoraria; Takeda: Honoraria; Janssen: Honoraria; BMS: Honoraria. Kastritis: Janssen: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Genesis Pharma: Honoraria; Amgen: Consultancy, Honoraria, Research Funding. Esteves: AbbVie: Consultancy; BMS: Consultancy; Amgen: Consultancy; Janssen: Consultancy. Delforge: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees. Yee: Karyopharm: Consultancy; Bristol Myers Squibb: Consultancy; Oncopeptides: Consultancy; Adaptive: Consultancy; GSK: Consultancy; Takeda: Consultancy; Amgen: Consultancy; Janssen: Consultancy; Sanofi: Consultancy. Arriola: AbbVie: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Ross: AbbVie: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company. Manthena: AbbVie: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Durie: Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda: Consultancy; Amgen: Other: fees from non-CME/CE services ." @default.
• W3214443089 created "2021-11-22" @default.
• W3214443089 creator A5006799794 @default.
• W3214443089 creator A5009032518 @default.
• W3214443089 creator A5011754600 @default.
• W3214443089 creator A5013530856 @default.
• W3214443089 creator A5018522443 @default.
• W3214443089 creator A5021012750 @default.
• W3214443089 creator A5026109406 @default.
• W3214443089 creator A5026574827 @default.
• W3214443089 creator A5027256584 @default.
• W3214443089 creator A5034605975 @default.
• W3214443089 creator A5036725271 @default.
• W3214443089 creator A5042397037 @default.
• W3214443089 creator A5044763057 @default.
• W3214443089 creator A5055089118 @default.
• W3214443089 creator A5057862805 @default.
• W3214443089 creator A5061550633 @default.
• W3214443089 creator A5067130875 @default.
• W3214443089 creator A5068934641 @default.
• W3214443089 date "2021-11-05" @default.
• W3214443089 modified "2023-09-28" @default.
• W3214443089 title "Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting" @default.
• W3214443089 doi "https://doi.org/10.1182/blood-2021-149336" @default.
• W3214443089 hasPublicationYear "2021" @default.
• W3214443089 type Work @default.
• W3214443089 sameAs 3214443089 @default.
• W3214443089 citedByCount "0" @default.
• W3214443089 crossrefType "journal-article" @default.
• W3214443089 hasAuthorship W3214443089A5006799794 @default.
• W3214443089 hasAuthorship W3214443089A5009032518 @default.
• W3214443089 hasAuthorship W3214443089A5011754600 @default.
• W3214443089 hasAuthorship W3214443089A5013530856 @default.
• W3214443089 hasAuthorship W3214443089A5018522443 @default.
• W3214443089 hasAuthorship W3214443089A5021012750 @default.
• W3214443089 hasAuthorship W3214443089A5026109406 @default.
• W3214443089 hasAuthorship W3214443089A5026574827 @default.
• W3214443089 hasAuthorship W3214443089A5027256584 @default.
• W3214443089 hasAuthorship W3214443089A5034605975 @default.
• W3214443089 hasAuthorship W3214443089A5036725271 @default.
• W3214443089 hasAuthorship W3214443089A5042397037 @default.
• W3214443089 hasAuthorship W3214443089A5044763057 @default.
• W3214443089 hasAuthorship W3214443089A5055089118 @default.
• W3214443089 hasAuthorship W3214443089A5057862805 @default.
• W3214443089 hasAuthorship W3214443089A5061550633 @default.
• W3214443089 hasAuthorship W3214443089A5067130875 @default.
• W3214443089 hasAuthorship W3214443089A5068934641 @default.
• W3214443089 hasConcept C126322002 @default.
• W3214443089 hasConcept C141071460 @default.
• W3214443089 hasConcept C143998085 @default.
• W3214443089 hasConcept C167135981 @default.
• W3214443089 hasConcept C2776063141 @default.
• W3214443089 hasConcept C2776364478 @default.
• W3214443089 hasConcept C2776694085 @default.
• W3214443089 hasConcept C2778524551 @default.
• W3214443089 hasConcept C2780108899 @default.
• W3214443089 hasConcept C2780401358 @default.
• W3214443089 hasConcept C2780739268 @default.
• W3214443089 hasConcept C71924100 @default.
• W3214443089 hasConcept C72563966 @default.
• W3214443089 hasConceptScore W3214443089C126322002 @default.
• W3214443089 hasConceptScore W3214443089C141071460 @default.
• W3214443089 hasConceptScore W3214443089C143998085 @default.
• W3214443089 hasConceptScore W3214443089C167135981 @default.
• W3214443089 hasConceptScore W3214443089C2776063141 @default.
• W3214443089 hasConceptScore W3214443089C2776364478 @default.
• W3214443089 hasConceptScore W3214443089C2776694085 @default.
• W3214443089 hasConceptScore W3214443089C2778524551 @default.
• W3214443089 hasConceptScore W3214443089C2780108899 @default.
• W3214443089 hasConceptScore W3214443089C2780401358 @default.
• W3214443089 hasConceptScore W3214443089C2780739268 @default.
• W3214443089 hasConceptScore W3214443089C71924100 @default.
• W3214443089 hasConceptScore W3214443089C72563966 @default.
• W3214443089 hasIssue "Supplement 1" @default.
• W3214443089 hasLocation W32144430891 @default.
• W3214443089 hasOpenAccess W3214443089 @default.
• W3214443089 hasPrimaryLocation W32144430891 @default.
• W3214443089 hasRelatedWork W2200095709 @default.
• W3214443089 hasRelatedWork W2302708051 @default.
• W3214443089 hasRelatedWork W2512928744 @default.
• W3214443089 hasRelatedWork W2810979422 @default.
• W3214443089 hasRelatedWork W2988277843 @default.
• W3214443089 hasRelatedWork W3094792334 @default.
• W3214443089 hasRelatedWork W3096445279 @default.
• W3214443089 hasRelatedWork W3121407702 @default.
• W3214443089 hasRelatedWork W3211465325 @default.
• W3214443089 hasRelatedWork W4285116674 @default.
• W3214443089 hasVolume "138" @default.
• W3214443089 isParatext "false" @default.
• W3214443089 isRetracted "false" @default.
• W3214443089 magId "3214443089" @default.
• W3214443089 workType "article" @default.